Literature DB >> 29205362

Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.

Justyna A Kucia-Tran1, Valtteri Tulkki1, Cinzia G Scarpini1, Stephen Smith1, Maja Wallberg1, Marta Paez-Ribes1, Angela M Araujo2, Jan Botthoff1, Maria Feeney3, Katherine Hughes4, Maria M Caffarel1,2,5, Nicholas Coleman1.   

Abstract

The oncostatin M (OSM) receptor (OSMR) shows frequent gene copy number gains and overexpression in cervical squamous cell carcinomas (SCCs), associated with adverse clinical outcomes. In SCC cells that overexpress OSMR, the major ligand OSM induces multiple pro-malignant effects, including invasion, secretion of angiogenic factors, and metastasis. Here, we demonstrate, for the first time, that OSMR overexpression in SCC cells activates cell-autonomous feed-forward signalling, via further expression of OSMR and OSM and sustained STAT3 activation, despite expression of the negative regulator suppressor of cytokine signalling 3 (SOCS3). The pro-malignant effects associated with OSMR overexpression are critically mediated by JAK-STAT3 activation, which is induced by exogenous OSM and also by autocrine OSM-OSMR interactions. Importantly, specific inhibition of OSM-OSMR interactions by neutralizing antibodies significantly inhibits STAT3 activation and feed-forward signalling, leading to reduced invasion, angiogenesis, and metastasis. Our findings are supported by data from 1254 clinical SCC samples, in which OSMR levels correlated with multiple cognate genes, including OSM, STAT3, and downstream targets. These data strongly support the development of OSM-OSMR-blocking antibodies as biologically targeted therapies against SCCs of the cervix and other anatomical sites.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  STAT3; cervix; head and neck; metastasis; neutralizing antibodies; oncostatin M receptor; squamous cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29205362     DOI: 10.1002/path.5010

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

Review 1.  Balancing STAT Activity as a Therapeutic Strategy.

Authors:  Kelsey L Polak; Noah M Chernosky; Jacob M Smigiel; Ilaria Tamagno; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2019-11-03       Impact factor: 6.575

2.  lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma.

Authors:  Zhaoyun Liu; Mei Han; Nanhao Meng; Jingyi Luo; Rong Fu
Journal:  Oxid Med Cell Longev       Date:  2021-08-11       Impact factor: 6.543

3.  Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.

Authors:  Angela M Araujo; Andrea Abaurrea; Peio Azcoaga; Joanna I López-Velazco; Sara Manzano; Javier Rodriguez; Ricardo Rezola; Leire Egia-Mendikute; Fátima Valdés-Mora; Juana M Flores; Liam Jenkins; Laura Pulido; Iñaki Osorio-Querejeta; Patricia Fernández-Nogueira; Nicola Ferrari; Cristina Viera; Natalia Martín-Martín; Alexandar Tzankov; Serenella Eppenberger-Castori; Isabel Alvarez-Lopez; Ander Urruticoechea; Paloma Bragado; Nicholas Coleman; Asís Palazón; Arkaitz Carracedo; David Gallego-Ortega; Fernando Calvo; Clare M Isacke; María M Caffarel; Charles H Lawrie
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 19.456

4.  Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.

Authors:  Carolyn D Hurst; Guo Cheng; Fiona M Platt; Olivia Alder; Emma Vi Black; Julie E Burns; Joanne Brown; Sunjay Jain; Jo-An Roulson; Margaret A Knowles
Journal:  J Pathol Clin Res       Date:  2022-03-14

Review 5.  Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer.

Authors:  Alessandra Caligiuri; Stefano Gitto; Giulia Lori; Fabio Marra; Maurizio Parola; Stefania Cannito; Alessandra Gentilini
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

6.  OSM/OSMR and Interleukin 6 Family Cytokines in Physiological and Pathological Condition.

Authors:  Francesca Lantieri; Tiziana Bachetti
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

7.  OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.

Authors:  Ken Tawara; Celeste Bolin; Jordan Koncinsky; Sujatha Kadaba; Hunter Covert; Caleb Sutherland; Laura Bond; Joseph Kronz; Joel R Garbow; Cheryl L Jorcyk
Journal:  Breast Cancer Res       Date:  2018-06-14       Impact factor: 6.466

8.  Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.

Authors:  Yuji Matsumoto; Tomotsugu Ichikawa; Kazuhiko Kurozumi; Yoshihiro Otani; Atsushi Fujimura; Kentaro Fujii; Yusuke Tomita; Yasuhiko Hattori; Atsuhito Uneda; Nobushige Tsuboi; Keisuke Kaneda; Keigo Makino; Isao Date
Journal:  Acta Neuropathol Commun       Date:  2020-04-05       Impact factor: 7.801

9.  Integrative transcriptomic analysis for linking acute stress responses to squamous cell carcinoma development.

Authors:  Tran N Nguyen; Kimal Rajapakshe; Courtney Nicholas; Leticia Tordesillas; Erik A Ehli; Christel M Davis; Cristian Coarfa; Elsa R Flores; Sally E Dickinson; Clara Curiel-Lewandrowski; Kenneth Y Tsai
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.